https://www.live-feeds.com/feed/novartis-to-license-drug-from-china-s-abogen-in-up-to-7-8-billion-dealContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/novartis-to-license-drug-from-china-s-abogen-in-up-to-7-8-billion-dealhttps://www.live-feeds.com/feed/novartis-to-license-drug-from-china-s-abogen-in-up-to-7-8-billion-deal#u102446Mon, 05 Oct 2026 11:41:04 +0000Novartis has agreed to license an experimental messenger RNA-based autoimmune therapy from Chinese biotechnology company Abogen Biosciences in an agreement valued at up to $7.8 billion. The therapeutic asset is an in vivo mRNA-encoded T-cell engager designed to produce a CD3xCD19 T-cell engager inside the human body. Abogen stated that this method could potentially lower the risk of dangerous cytokine release. The transaction expands a growing trend of Western pharmaceutical firms sourcing early-stage innovation from Chinese biotech startups.Why it mattersLarge pharmaceutical corporations are